NasdaqGM:TRVIPharmaceuticals
Assessing Trevi Therapeutics (TRVI) Valuation After FDA Alignment On Phase 3 IPF Chronic Cough Program
Trevi Therapeutics (TRVI) has secured FDA alignment on its clinical plan for nalbuphine ER in IPF related chronic cough, clearing the way for two randomized, double blind, placebo controlled Phase 3 trials starting later this year.
See our latest analysis for Trevi Therapeutics.
That FDA alignment comes after a recent pullback, with a 7 day share price return showing a decline of 17.22% and a 90 day share price return showing a decline of 12.69%. However, the 1 year total shareholder return...